HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00922636

A Fixed-Dose, Study of LY2216684 in Pediatric people with Attention Deficit/Hyperactivity Disorder

Researchers compared LY2216684, methylphenidate and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.

Medication studyAges 6–17Canada + United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared LY2216684, methylphenidate and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.

Who was this study for?

This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.

Listed locations
Spring Valley and 18 more locationsSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study clarity

Study information

Study start dateJune 2009
Recruitment status
Completed
Enrollment listed in the registry
340
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States, Canada
Age range
From 6 Years to 17 Years
Official registry ID
NCT00922636
Official title
Show the full official title

A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Spring Valley, United States · Bradenton, United States · Gainesville, United States

16 more locations
  • Orlando, United States
  • Indianapolis, United States
  • Lincoln, United States
  • Omaha, United States
  • Las Vegas, United States
  • Canton, United States
  • Portland, United States
  • Media, United States
  • Norristown, United States
  • Memphis, United States
  • Lake Jackson, United States
  • Lubbock, United States
  • Wharton, United States
  • Herndon, United States
  • Kelowna, Canada
  • Santurce, Puerto Rico
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

Researchers compared LY2216684, methylphenidate and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including LY2216684, Methylphenidate, Placebo (tablet) and Placebo (capsule).

Who was this study for?

This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies